To investigate a cohort of patients undergoing active surveillance (AS) for localized prostate cancer (PCa) with regard to possible differences in discontinuation rates, subsequent therapies, reasons for intervention and pathological findings after deferred surgery after patient stratification into very-low-risk, low-risk and intermediate-/ high-risk PCa groups.
Introduction
Since the introduction of PSA screening for prostate cancer (PCa) a stage shift towards localized and well-differentiated tumours has been observed [1] . This has led to a decrease in disease-specific mortality but also to overdiagnosis and overtreatment of cancers that often have no effect on life expectancy [2] . Active surveillance (AS) is a conservative approach for patients with localized PCa and a favourable risk profile, intending to reduce overtreatment of clinically insignificant disease by radical intervention [3] . Patients remain under close surveillance (DRE, PSA assessment, rebiopsies) and invasive treatment is only recommended when signs of progression occur. With a 10-year cancer-specific survival rate of >98.0% [4, 5] , AS outcomes do not differ from those of radical prostatectomy (RP) or radiation therapy (RT) [6] [7] [8] . The average 5-and 10-year probabilities of discontinuing AS are 33% and 55%, respectively [9] .
There is no broad agreement on acceptable eligibility criteria for AS, instead they are applied rather inconsistently in various clinical trials. Most studies have confined AS to patients in the low-risk category according to DꞋAmico classification (cT ≤2a, PSA ≤10 ng/mL, Gleason score ≤6) [10] , whereas some trials used the more restrictive criteria of very-low-risk PCa introduced by Epstein (Gleason score ≤6, ≤2 positive biopsy cores, <50% cancer involvement, PSA ≤10 ng/mL, PSA density ≤0.15 ng/mL/ mL) [11] . Some programmes offered AS also for patients in the intermediate-risk group (cT ≤2b, PSA 10-20 ng/mL, Gleason score ≤7) [4, 12, 13] .
Against this background, the present cohort of 468 patients undergoing AS in the German HAROW study was stratified into three risk groups (very low, low and intermediate/high) in order to examine if stratification yields differences regarding AS discontinuation rates, subsequent therapies, reasons for intervention and pathological findings after deferred RP.
Patients and Methods

Study Design
Initiated in 2008, the HAROW study was a prospective, noninterventional, observational outcomes research study in the community setting [14] , offering various treatment options to patients with localized PCa: hormone therapy (HT), AS, RT, RP or watchful waiting, with special interest in AS, at the time a relatively new non-invasive therapy with curative intent. Upon signs of progression, patients were advised to opt for invasive therapy (RP or RT), or HT.
From July 2008 to July 2013, 2957 patients with newly diagnosed localized (≤T2c) PCa were prospectively enrolled by 259 physicians, of whom 86% were office-based urologists. A total of 468 patients (15.8%) underwent AS. Clinical variables, tumour characteristics (DRE, PSA levels, Gleason score) as well as information on therapeutic approach, and clinical course of disease were compiled at study entry and every 6 months thereafter. Comorbidities were evaluated using the Charlson comorbidity index [15] .
Inclusion and Follow-up
Because of the non-interventional character of the study, only recommendations regarding inclusion in and discontinuation of AS were given. Because AS was a largely unknown strategy at the beginning of the study, and no guidelines were available at that time, recommendations for an inclusion in AS (≤cT2c, PSA ≤10 ng/mL, Gleason score ≤6, PSA density ≤0.2 ng/mL/mL and ≤2 positive biopsies) correspond to those available in the literature [11, 16, 17] . The recommended follow-up procedure included DRE, PSA and PSA doubling time (PSA-DT) every 3 months in the first 2 years, and every 6 months thereafter. Re-biopsy was recommended after 1 year, and then every 3 years. Recommendations for AS discontinuation included histological evidence of progressive disease, increasing PSA levels with PSA-DT <3 years, clinical signs of progression on DRE, or patient's request.
Risk Group Stratification
For the present analysis patients undergoing AS were stratified into three groups: (i) very-low-risk (≤cT2a disease, PSA ≤10 ng/mL, Gleason score ≤6, PSA density ≤0.2 ng/mL/ mL and ≤2 positive biopsies); (ii) low-risk (≤cT2a disease, PSA ≤10 ng/mL, Gleason score ≤6, and not fulfilling very low-risk criteria); and (iii) intermediate-/high-risk: patients with an intermediate risk profile (cT2b disease or PSA ≥10-20 ng/mL or Gleason score 7) or high risk profile (cT2c disease or PSA ≥20 ng/mL or Gleason score ≥8) according to the D'Amico criteria [10] .
Statistical Analysis
The risk groups were compared with regard to rates of discontinuation of AS, subsequent therapies, reasons for intervention and pathological findings after deferred RP.
Data were analysed using IBM's statistical program SPSS, version 22 (Armonk, NY, USA). The metric variables were evaluated through univariate ANOVA. Categorical variables were analysed using the chi-squared test or Fisher's exact test. The Kaplan-Meier method and the log-rank test were used to analyse the treatment-free period. The significance level was set to 5% for all calculations.
Ethics
All procedures performed in the studies were in accordance with the ethical standards of the Ethics Committee of the State Chamber of Medicine in Bavaria and with the 1964 Helsinki Declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.
Results
The AS programme was selected for 468 patients (15.8%; n = 2957), including 386 patients (33.5%) with very-low-risk and low-risk tumours (n = 1151), 66 patients (6.8%) with intermediate-risk tumours (n = 965), and 14 patients (1.8%) with high-risk tumours (n = 788; 1.8% missing).
Of the 468 patients undergoing AS, 244 (52.1%) were in the very-low-risk and 142 (30.3%) were in the low-risk group, whilst 82 patients (17.5%) were in the intermediate-/high-risk group, which was composed of 68 patients with an intermediate-risk profile and 14 patients with a high-risk profile according to D'Amico classification [10] .
Patient characteristics are shown in Table 1A . Intermediate-/ high-risk patients had higher mean PSA values and PSA density (P ≤ 0.001). No differences among the groups were seen in age and comorbidities. A separate observation of the intermediate-/high-risk group is shown in Table 1B , which shows that 10/14 patients were only in the high-risk group because they had clinical T-category 2c disease.
The median follow-up of the AS patients was 27.4 months, and the mean follow-up was 28.5 months. After this period, 112 patients (23.9%) discontinued AS and switched to another treatment. The discontinuation rates were 62/244 (25.4%) for the very-low-risk, 30/142 (21.1%) for the low-risk and 20/82 (24.4%) for the intermediate-/high-risk groups, with no significant differences among the groups (P = 0.633).
A total of 105 patients (22.4%) discontinued AS in favour of an invasive treatment, of whom 65 (61.9%) chose RP, 30 Table 2A . No significant differences among the three risk groups were observed (P = 0.495).
The calculated Kaplan-Meier curves for the probability of remaining without an invasive treatment are shown in Fig. 1 After deferred RP in 65 patients, locally advanced disease (≥pT3) was seen in 12.3% and a Gleason score ≥7b in 20.0%, with no significant differences among the groups (P = 0.6; P = 0.22 [ Table 3 ]). No patient died and no patient developed metastasis during the course of follow-up.
Discussion
Selection criteria in clinical AS trials are used inconsistently. While in most series AS is intended for patients with verylow-risk or low-risk tumours [5, 18, 19] , there are a few series that use a less stringent set of inclusion criteria. The Toronto cohort included patients aged ≥70 years with PSA ≤15 ng/mL or Gleason score ≤3 + 4 during the first 4 years of the study [4] , and the University of California, San Francisco (UCSF) admitted patients with Gleason score ≤7 [20] . Two screening trials also included patients with intermediate-risk disease: the European Randomized Study of Screening for Prostate Cancer (ERSPC) for the cohort of screen-detected patients [12] prior to the ERSPC-affiliated Prostate Cancer Research International Study (PRIAS) [19] and the Gothenburg screening trial [13] . The proportions of patients with intermediate-risk disease in these trials were 25% and 22%, respectively.
Recently, data from the first prospective, randomized trial comparing AS, RP and RT (ProtecT) demonstrated no significant differences in the PCa-specific mortality at a median of 10 years, while AS was associated with a higher incidence of disease progression and metastases [6] . Study participants were mainly in the low-risk group (cT1c = 75%, Gleason 6 = 77%, PSA ≤10 ng/mL = 89%), a comparison with the intermediate-or high-risk groups was not provided.
The data from the HAROW study, which was designed to evaluate the outcome of five different treatment options for unselected patients with localized PCa, reflect 'everyday conditions', and thus the current treatment pattern among German urologists at the time. Because of the noninterventional study design and the absence of stringent entry specifications for AS, it was possible to include patients with higher risk features in the AS cohort. Nevertheless, 82.5% of patients undergoing AS had a very-low-risk or low-risk profile, which indicates good patient selection by the investigators. Most of the 82 patients (17.5%) who did not present with very-low-risk and low-risk profiles had intermediate-risk PCa; only 14 patients were at high risk, including 10 patients rated as high risk only because of a clinical T-category T2c.
In the present study the probability of remaining without invasive treatment did not differ significantly among the three risk groups during the mean follow-up of 28.5 months. Similar results were found in the UCSF series where low-and intermediate-risk patients did not differ in terms of progression-free survival, defined as no Gleason upgrade or PSA-DT ≤2 years, or in terms of discontinuation of AS within 4 years after diagnosis [20] . The ERSPC series could not demonstrate a difference in the estimated 10-year diseasespecific survival rates between patients in the low-risk and intermediate-risk categories (99.1% vs 96.1%), but those in the intermediate-risk group were more likely to undergo an invasive treatment during a mean follow-up of 7.4 years (53.9% vs 39.9%) [12] .
The Toronto cohort is one of the largest AS cohorts, with 980 patients, including 25% in the intermediate-risk group, and with a follow-up of up to 16 years. The 10-and 15-year disease-specific survival rates for the total cohort were 98.1% and 94.3%, respectively (no subgroup analysis of the different risk groups was provided) [4] . Examining all 30 patients who developed metastasis in the Toronto cohort, Yamamoto et al. [21] found a higher risk of metastatic progression in patients with intermediate-risk disease, except in those with Gleason score 6 and PSA ≥10 ng/mL.
The assumption, based on the above-mentioned findings, that even intermediate-risk patients may safely be monitored with AS is contradicted by the long-term results of the Gothenburg screening trial in 474 patients, stratified into very-low-risk, low-risk and intermediate-risk groups, with a mean follow-up of 8 years [13] . The 15-year failure-free survival was only 40% for the intermediate-risk and 77% for the low-risk groups, 'failure' after AS being defined as an incurable state of the disease (metastases, PSA recurrence after RP or RT, or death from PCa). The 15-year diseasespecific survival rates for the very-low-risk, low-risk and intermediate-risk groups were 100%, 94% and 90%, respectively. Based on their findings, the authors concluded that 'it is questionable, whether AS can be safely recommended for men who are not at very low risk and have a long remaining life expectancy'. Their results emphasize that 'time after diagnosis' is a determining factor because the disease-specific survival was nearly 100% after 10-12 years, but then started to decline.
Given the so-far short follow-up period in the HAROW study, our results are in line with the results of AS cohorts with a short-to intermediate follow-up; it is, however, foreseeable, that the probability curves of remaining without invasive treatment will diverge with a longer follow-up period.
In the present study, subsequent therapies after termination of AS did not vary significantly among the risk groups. These findings are consistent with the results of the UCSF series Table 3 Pathological findings in deferred radical prostatectomy after termination of active surveillance for all three risk groups (n.a. = not available).
Total
Very low risk Low risk Int./high risk P (n = 65) (n = 37) (n = 18) (n = 10) [20] , whereas in the ERSPC cohort the low-risk group received significantly more RT and less HT than the intermediate-risk group [12] .
Interestingly, the main reason for intervention differed significantly among the groups in the present study. While in the very-low-risk and low-risk group most patients received an invasive treatment because of a biopsy upgrade or PSA increase, in the intermediate-/high-risk group most patients switched at their own preference. This was not observed in other AS series. While this finding could partly be attributable to the small number of patients or to the patient 0 s greater freedom of choice based on the HAROW study's specific design, it may also indicate that patients with higher-risk features have a greater fear of tumour progression. The latter could be explained by the observation that patients undergoing AS tend to strongly overestimate their mortality risk [22] .
Deferred RP for initially conservatively managed patients with very-low-risk or low-risk tumours results in an upstaging of 12% and an upgrading of 34% [23] . The present study results confirm the rates for upstaging, with a rate of 12.3%; however, the rates for upgrading (Gleason score ≥7) were high (56.9%), and probably even higher, as pathological results were not available in 11 out of 65 RP specimens (16.9%). As 17.5% of the patients in the present cohort were at intermediate or high risk, these higher rates are not surprising, and are similar to the results of the UCSF series, with 70% of the patients upgraded at repeat biopsy and/or at RP, and with 15% having positive margins [20] .
The present data show a poor correlation of initial risk groups with upgrading and upstaging. This could partly be explained by the low number of patients with deferred RP, but is consistent with the results of the Canadian Prostate Cancer Active Surveillance Study (PASS), including 103 patients who underwent RP after initial AS. In that cohort, 32-40% had adverse pathological features (Gleason pattern ≥4, extraprostatic extension, seminal vesicle invasion, lymph node metastases), irrespective of the initial risk classification [24] .
Several authors have analysed the reliability of different AS protocols based on pathological features of surgical specimens in patients who met the various criteria for AS protocols, but opted for RP. Based on their findings the PRIAS criteria (≤ cT2c, PSA ≤10 ng/mL, Gleason score ≤6, PSA density ≤0.2 ng/mL/mL and ≤2 positive biopsies) [19] , which are identical to the HAROW recommendations for AS, have demonstrated the highest ability to identify patients with insignificant PCa [25] [26] [27] .
Limitations of the present study include the short follow-up period for tumours of slow growth, which meant it was not possible to assess the endpoints of metastasis and mortality. However, AS series with longer follow-up show that the majority of patients discontinue AS within the first 3 years, probably not because of tumour progression but because of an initial underestimation of the extent of the disease [9] . In addition, the pathological reports of RP specimens did not yield information about positive margins and were missing in 11 out of 64 cases. Lastly, central pathological review was not performed; however, this is rarely carried out in community practice and this multicentre approach reflects the realities of everyday care.
In conclusion, the results of the present study show differences in the discontinuation rates, subsequent therapies and pathological findings after deferred RP for patients with localized PCa undergoing AS, stratified according to the Epstein and D'Amico criteria into very-low-risk, low-risk and intermediate-/high-risk groups. These findings are in line with other AS series with short-to intermediate-term follow-up, as significant differences seem to occur at the earliest after 10-12 years [13] . A longer-term follow-up would be required to answer the question of whether patients with intermediate-risk tumours could safely be managed with AS. Based on the data in the literature, it could be assumed that it is not a safe approach for every patient with intermediate-risk tumours, but with the availability of new imaging techniques, primarily multiparametric MRI, AS might be considered for patients with intermediate-risk PCa and Gleason score 6 (or possibly 7a with a small percentage of Gleason 4 pattern) and a life expectancy of 10-15 years who refuse to undergo invasive treatment.
In the present study patients with intermediate-/high-risk tumours tend to request invasive treatment during the course of AS more frequently than patients with lower-risk features, which could be an indicator of a higher level of anxiety in such patients.
